Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: Systematic literature review and analysis of a monocentric cohort

Autoimmunity Reviews

Volumn 13, Issue 8, 2014, Pages 873-879

  Piga, Matteo ^a   Chessa, Elisabetta ^a   Ibba, Valentina ^a   Mura, Valentina ^a   Floris, Alberto ^a   Cauli, Alberto ^a   Mathieu, Alessandro ^a  

^a DEPARTMENT OF RADIOLOGY   (Italy)

Author keywords

Anti TNF alpha; Biologic drugs; Drug induced glomerulonephritis; Lupus nephritis; Rheumatic diseases; Systemic vasculitis

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; ETANERCEPT; INFLIXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE RENAL DISORDER; CHRONIC ARTHRITIS; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE DURATION; DRUG SAFETY; FOLLOW UP; GLOMERULONEPHRITIS; HISTOPATHOLOGY; HUMAN; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FUNCTION; LUPUS LIKE SYNDROME; PROTEIN URINE LEVEL; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; SYSTEMIC VASCULITIS; UREA NITROGEN BLOOD LEVEL; URINALYSIS; URINE SEDIMENT;

ANTI-TNF-ALPHA; BIOLOGIC DRUGS; DRUG-INDUCED GLOMERULONEPHRITIS; LUPUS NEPHRITIS; RHEUMATIC DISEASES; SYSTEMIC VASCULITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CHRONIC DISEASE; COHORT STUDIES; HUMANS; KIDNEY DISEASES;

EID: 84902137888     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.05.005     Document Type: Review

References (46)

1. Smolen J.S., Landewe R., Breedveld F.C., Buch M., Burmester G., Dougados M., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014, 73:492-509.
2. Smolen J.S., Braun J., Dougados M., Emery P., Fitzgerald O., Helliwell P., et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014, 73:6-16.
3. Paula F.S., Alves J.D. Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis. Biogeosciences 2014, 8:1-12.
4. Noack M., Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 2014, 13:668-677.
5. Dimitroulas T., Nikas S.N., Trontzas P., Kitas G.D. Biologic therapies and systemic bone loss in rheumatoid arthritis. Autoimmun Rev 2013, 12:958-966.
6. Modena V., Bianchi G., Roccatello D. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?. Autoimmun Rev 2013, 12:835-838.
7. Roccatello D. Novel diagnostic approaches and cost-benefit balance of treatment of immune-mediated and rare disease in the era of biologic drugs: lessons from the 15th Turin Congress on Immune Pathology and Orphan Disease. Autoimmun Rev 2013, 12:793-795.
8. Ramos-Casals M., Roberto Perez A., Diaz-Lagares C., Cuadrado M.J., Khamashta M.A. Autoimmune diseases induced by biological agents: a double-edged sword?. Autoimmun Rev 2010, 9:188-193.
9. Perez-Alvarez R., Perez-de-Lis M., Ramos-Casals M. Biologics-induced autoimmune diseases. Curr Opin Rheumatol 2013, 25:56-64.
10. Kaneko K., Nanki T., Hosoya T., Mizoguchi F., Miyasaka N. Etanercept-induced necrotizing crescentic glomerulonephritis in two patients with rheumatoid arthritis. Mod Rheumatol 2010, 20:632-636.
11. Kaushik P., Rahmani M., Ellison W. Membranous glomerulonephritis with the use of etanercept in ankylosing spondylitis. Ann Pharmacother 2011, 45:e62.
12. Maruotti N., Corrado A., Gaudio A., Cantatore F.P. Membranous nephropathy in rheumatoid arthritis: a case report. Clin Exp Rheumatol 2009, 27:840-842.
13. Stokes M.B., Foster K., Markowitz G.S., Ebrahimi F., Hines W., Kaufman D., et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005, 20:1400-1406.
14. den Broeder A.A., Assmann K.J., van Riel P.L., Wetzels J.F. Nephrotic syndrome as a complication of anti-TNFalpha in a patient with rheumatoid arthritis. Neth J Med 2003, 61:137-141.
15. Jacquet A., Francois H., Frangie C., Yahiaoui Y., Ferlicot S., Micelli C., et al. IgA nephropathy associated with ankylosing spondylitis is not controlled by infliximab therapy. Nephrol Dial Transplant 2009, 24:3540-3542.
16. Matsuo Y., Mizoguchi F., Kohsaka H., Ito E., Eishi Y., Miyasaka N. Tocilizumab-induced immune complex glomerulonephritis in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2013, 52:1341-1343.
17. Michel M., Henri P., Vincent F., Leon N., Marcelli C. Mesangial immunoglobulin (Ig)A glomerulonephritis in a patient with rheumatoid arthritis treated with abatacept. Joint Bone Spine 2013, 80:660-663.
18. Korsten P., Sweiss N.J., Nagorsnik U., Niewold T.B., Grone H.J., Gross O., et al. Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab. Am J Kidney Dis 2010, 56:e17-e21.
19. Nishimura K., Saegusa J., Kawano S., Morinobu A. Tumor necrosis factor-alpha inhibitor-induced antiglomerular basement membrane antibody disease in a patient with rheumatoid arthritis. J Rheumatol 2012, 39:1904-1905.
20. Tosovsky M., Bradna P., Laco J., Podhola M., Soukup T., Brozik J. Case1-2012: ANCA associated glomerulonephritis in combination with IgG4-positive mediastinal mass in a patient with ankylosing spondylitis treated with TNF alpha inhibitors. Acta Med (Hradec Kralove) 2012, 55:42-46.
21. Ashok D., Dubey S., Tomlinson I. C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab. Clin Rheumatol 2008, 27:261-264.
22. Simms R., Kipgen D., Dahill S., Marshall D., Rodger R.S. ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy. Am J Kidney Dis 2008, 51:e11-e14.
23. Doulton T.W., Tucker B., Reardon J., Velasco N. Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis. Clin Nephrol 2004, 62:234-238.
24. Duffy T.N., Genta M., Moll S., Martin P.Y., Gabay C. Henoch Schonlein purpura following etanercept treatment of rheumatoid arthritis. Clin Exp Rheumatol 2006, 24:S106.
25. Roux C.H., Brocq O., Albert C.B.V., Euller-Ziegler L. Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis. Joint Bone Spine 2004, 71:444-445.
26. Lee A., Kasama R., Evangelisto A., Elfenbein B., Falasca G. Henoch-Schonlein purpura after etanercept therapy for psoriasis. J Clin Rheumatol 2006, 12:249-251.
27. Reitblat T., Reitblat O. Appearance of ANCA - associated vasculitis under tumor necrosis factor-alpha inhibitors treatment. Am J Case Rep 2013, 14:80-82.
28. Rolle A.S., Zimmermann B., Poon S.H. Etanercept-induced Henoch-Schonlein purpura in a patient with ankylosing spondylitis. J Clin Rheumatol 2013, 19:90-93.
29. Mor A., Bingham C., Barisoni L., Lydon E., Belmont H.M. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol 2005, 32:740-743.
30. Piccolo T., Lisi P., Valicenti E., Pannarale G., P.C Clinical and histological features of lupus nephritis induced by anti-TNFα therapy. NDT plus 2008, 4:221-224.
31. Kronbichler A., Mayer G. Renal involvement in autoimmune connective tissue diseases. BMC Med 2013, 11:95.
32. Piga M., Gabba A., Cauli A., Garau P., Vacca A., Mathieu A. Rituximab treatment for 'rhupus syndrome': clinical and power-Doppler ultrasonographic monitoring of response. A longitudinal pilot study. Lupus 2013, 22:624-628.
33. Mustila A., Korpela M., Mustonen J., Helin H., Huhtala H., Soppi E., et al. Perinuclear antineutrophil cytoplasmic antibody in rheumatoid arthritis: a marker of severe disease with associated nephropathy. Arthritis Rheum 1997, 40:710-717.
34. Kemp E., Nielsen H., Petersen L.J., Gam A.N., Dahlager J., Horn T., et al. Newer immunomodulating drugs in rheumatoid arthritis may precipitate glomerulonephritis. Clin Nephrol 2001, 55:87-88.
35. Koya M., Pichler R., Jefferson J. Minimal-change disease secondary to etanercept. Clin Kidney J 2012, 5:420-423. [2012].
36. Chen T.J., Yang Y.F., Huang P.H., Lin H.H., Huang C.C. Permanent renal loss following tumor necrosis factor alpha antagonists for arthritis. Rheumatol Int 2012, 30:1077-1079.
37. Gupta A., Pendyala P., Arora P., Sitrin M.D. Development of the nephrotic syndrome during treatment of Crohn's disease with adalimumab. J Clin Gastroenterol 2011, 45:e30-e33.
38. Hatakeyama T., Komatsuda A., Matsuda A., Togashi M., Maki N., Masai R., et al. Renal amyloidosis associated with extracapillary glomerulonephritis and vasculitis in a patient with inflammatory bowel disease treated with infliximab. Clin Nephrol 2008, 70:240-244.
39. Yahya T.M., Dhanyamraju S., Harrington T.M., Prichard J.W. Spontaneous resolution of lupus nephritis following withdrawal of etanercept. Ann Clin Lab Sci 2013, 43:447-449.
40. De Bandt M., Sibilia J., Le Loet X., Prouzeau S., Fautrel B., Marcelli C., et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005, 7:R545-R551.
41. Saint Marcoux B., De Bandt M. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 2006, 73:710-713.
42. Ramos-Casals M., Brito-Zeron P., Munoz S., Soria N., Galiana D., Bertolaccini L., et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007, 86:242-251.
43. Costa M.F., Said N.R., Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008, 37:381-387.
44. Ramos-Casals M., Brito-Zeron P., Cuadrado M.J., Khamashta M.A. Vasculitis induced by tumor necrosis factor-targeted therapies. Curr Rheumatol Rep 2008, 10:442-448.
45. Becher B., Blain M., Giacomini P.S., Antel J.P. Inhibition of Th1 polarization by soluble TNF receptor is dependent on antigen-presenting cell-derived IL-12. J Immunol 1999, 162:684-688.
46. Prinz J.C. Autoimmune-like syndromes during TNF blockade: does infection have a role?. Nat Rev Rheumatol 2011, 7:429-434.